Skip to main content
. Author manuscript; available in PMC: 2022 Sep 27.
Published in final edited form as: J Biomed Nanotechnol. 2019 Nov 1;15(11):2229–2239. doi: 10.1166/jbn.2019.2859

Scheme 1. Illustration of therapy with FC+ Nanobody.

Scheme 1.

DC fusion cells (DC/tumor fusion cells, FCs) are generated. Nanobody against CTLA-4 (CTLA-4 Nb16) eliminates immunosuppression via disrupting CTLA-4-mediated negative costimulation in T cells induced by dendritic cell/tumor fusion cells. Finally, the induced-CTLs were transferred to kill tumor cells.